Develop and optimize downstream unit operations for mRNA drug substance: DNase treatment and reaction quench, clarification and depth filtration, chromatographic capture and polishing (oligo-dT affinity, ion exchange, reverse phase, hydrophobic interaction, core bead or multimodal), precipitation-based purification, TFF/UFDF, and sterile filtration. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY (exagamglogene autotemcel [exa-cel]), the world's first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.